Presurgical levels of circulating tumour DNA in patients with resectable chemotherapy-naïve colorectal liver metastases: association with multiorgan recurrence and survival in the MIRACLE cohort.
A cheap blood test measuring tumor DNA before surgery can identify which colorectal cancer patients need closer monitoring after treatment.
Pre-surgical ctDNA measurement using an affordable mFast-SeqS assay independently predicted 3-fold increased risk of poor survival in resectable colorectal liver metastases (n=182). This minimally invasive test could identify high-risk patients upfront before local treatment decisions.
What the study was
- Study design
- Retrospective cohort study
- Population
- Patients with resectable, chemotherapy-naïve colorectal liver metastases (CRLM), n=182
- Sample size
- 182
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- The British Journal of Surgery
Why it surfaced
Well-designed retrospective cohort from Rotterdam validates affordable ctDNA test for risk stratification in resectable CRLM; actionable for treatment planning.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.